Cancer immunotherapy via dendritic cells

[1]  H. Ueno,et al.  IL-12 receptor β1 deficiency alters in vivo T follicular helper cell response in humans. , 2013, Blood.

[2]  Virginia Pascual,et al.  Induction of ICOS+CXCR3+CXCR5+ TH Cells Correlates with Antibody Responses to Influenza Vaccination , 2013, Science Translational Medicine.

[3]  V. Soumelis,et al.  Human inflammatory dendritic cells induce Th17 cell differentiation. , 2013, Immunity.

[4]  G. Nabel.  Designing tomorrow's vaccines. , 2013, The New England journal of medicine.

[5]  W. Oyen,et al.  Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. , 2013, Cancer research.

[6]  A. Palucka,et al.  Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet? , 2013, Science.

[7]  Drew A. Torigian,et al.  Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer , 2013, Oncoimmunology.

[8]  Yong‐jun Liu,et al.  The E3 ubiquitin ligase TRIM21 negatively regulates the innate immune response to intracellular double-stranded DNA , 2012, Nature Immunology.

[9]  E. Klechevsky,et al.  Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming , 2012, Proceedings of the National Academy of Sciences.

[10]  L. Zitvogel,et al.  Trial watch , 2012, Oncoimmunology.

[11]  I. Mellman,et al.  Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. , 2012, Blood.

[12]  H. Nisenbaum,et al.  HER‐2 pulsed dendritic cell vaccine can eliminate HER‐2 expression and impact ductal carcinoma in situ , 2012, Cancer.

[13]  Michael Poidinger,et al.  Human Tissues Contain CD141hi Cross-Presenting Dendritic Cells with Functional Homology to Mouse CD103+ Nonlymphoid Dendritic Cells , 2012, Immunity.

[14]  O. Joffre,et al.  Cross-presentation by dendritic cells , 2012, Nature Reviews Immunology.

[15]  S. Tangye,et al.  The origins, function, and regulation of T follicular helper cells , 2012, The Journal of experimental medicine.

[16]  K. Ishii,et al.  Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination , 2012, Nature Reviews Immunology.

[17]  E. Klechevsky,et al.  The differential production of cytokines by human Langerhans cells and dermal CD14(+) DCs controls CTL priming. , 2012, Blood.

[18]  D. Le,et al.  Clinical development of Listeria monocytogenes-based immunotherapies. , 2012, Seminars in oncology.

[19]  G. Altan-Bonnet,et al.  Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. , 2012, Blood.

[20]  V. Soumelis,et al.  Characterization of resident and migratory dendritic cells in human lymph nodes , 2012, The Journal of experimental medicine.

[21]  R. Steinman.  Decisions about dendritic cells: past, present, and future. , 2012, Annual review of immunology.

[22]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[23]  Shuzhao Li,et al.  Systems vaccinology: learning to compute the behavior of vaccine induced immunity , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.

[24]  K. Murphy,et al.  Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3(-/-) mice. , 2012, Molecular immunology.

[25]  J. Banchereau,et al.  Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10–producing suppressive CD4+ T cells , 2012, The Journal of experimental medicine.

[26]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[27]  P. Greenberg.  Ralph M. Steinman: A man, a microscope, a cell, and so much more , 2011, Proceedings of the National Academy of Sciences.

[28]  J. Cyster,et al.  How T cells earn the follicular rite of passage. , 2011, Immunity.

[29]  Jacob T. Robinson,et al.  Systematic Discovery of TLR Signaling Components Delineates Viral-Sensing Circuits , 2011, Cell.

[30]  K. Ravichandran.  Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. , 2011, Immunity.

[31]  W. Oyen,et al.  Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3′-fluoro-3′-deoxy-thymidine ([18F]FLT) PET imaging , 2011, Proceedings of the National Academy of Sciences.

[32]  Yong‐jun Liu,et al.  The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells , 2011, Nature Immunology.

[33]  R. V. van Lier,et al.  Cutting Edge: Virus Selectively Primes Human Langerhans Cells for CD70 Expression Promoting CD8+ T Cell Responses , 2011, The Journal of Immunology.

[34]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[35]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[36]  M. Merad,et al.  Dendritic cell and macrophage heterogeneity in vivo. , 2011, Immunity.

[37]  D. Busch,et al.  Regulatory T Cells Selectively Control CD8+ T Cell Effector Pool Size via IL-2 Restriction , 2011, The Journal of Immunology.

[38]  Michael J. Bevan,et al.  CD8+ T Cells: Foot Soldiers of the Immune System , 2011, Immunity.

[39]  K. Mills,et al.  TLR based therapeutics. , 2011, Current opinion in pharmacology.

[40]  W. Oyen,et al.  Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients , 2011, Clinical Cancer Research.

[41]  Scott N. Mueller,et al.  Targeting Antigen to Mouse Dendritic Cells via Clec9A Induces Potent CD4 T Cell Responses Biased toward a Follicular Helper Phenotype , 2011, The Journal of Immunology.

[42]  J. Kirkwood,et al.  Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? , 2011, Immunologic research.

[43]  G. Cheng,et al.  DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. , 2011, Immunity.

[44]  Li Wu,et al.  Human Dendritic Cell Subsets from Spleen and Blood Are Similar in Phenotype and Function but Modified by Donor Health Status , 2011, The Journal of Immunology.

[45]  K. Blackwell,et al.  Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients , 2011, Clinical Cancer Research.

[46]  Hisataka Kobayashi,et al.  Cancer Cell-Selective In Vivo Near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules , 2011, Nature Medicine.

[47]  M. Hellmich,et al.  Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis , 2011, PloS one.

[48]  R. Steinman,et al.  Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates , 2011, Proceedings of the National Academy of Sciences.

[49]  Ping Zhang,et al.  Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity , 2011, Nature Medicine.

[50]  M. Braga,et al.  Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer , 2011, The Journal of experimental medicine.

[51]  C. Aspord,et al.  Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation , 2011, The Journal of experimental medicine.

[52]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[53]  A. Houghton,et al.  Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo , 2011, Clinical Cancer Research.

[54]  L. Zitvogel,et al.  How to improve the immunogenicity of chemotherapy and radiotherapy , 2011, Cancer and Metastasis Reviews.

[55]  C. Figdor,et al.  Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines. , 2011, Seminars in immunology.

[56]  G. Barber,et al.  Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. , 2011, Current opinion in immunology.

[57]  H. Ueno,et al.  Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. , 2011, Immunity.

[58]  J. Engh,et al.  Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Christian A. Luber,et al.  Mouse CD8α+ DCs and human BDCA3+ DCs are major producers of IFN-λ in response to poly IC , 2010, The Journal of experimental medicine.

[60]  R. Steinman,et al.  Microbial Stimulation Fully Differentiates Monocytes to DC-SIGN/CD209+ Dendritic Cells for Immune T Cell Areas , 2010, Cell.

[61]  Sylvia Janetzki,et al.  Improved Endpoints for Cancer Immunotherapy Trials , 2010, Journal of the National Cancer Institute.

[62]  J. Banchereau,et al.  Concomitant Activation and Antigen Uptake via Human Dectin-1 Results in Potent Antigen-Specific CD8+ T Cell Responses , 2010, The Journal of Immunology.

[63]  E. Klechevsky,et al.  Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. , 2010, Blood.

[64]  Ash A. Alizadeh,et al.  Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma , 2010, Cell.

[65]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[66]  B. Pulendran,et al.  Activation of β-Catenin in Dendritic Cells Regulates Immunity Versus Tolerance in the Intestine , 2010, Science.

[67]  G. Schuler.  Dendritic cells in cancer immunotherapy , 2010, European journal of immunology.

[68]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[69]  H. Ueno,et al.  Dendritic Cells: Are They Clinically Relevant? , 2010, Cancer journal.

[70]  E. Jaffee,et al.  Cellular Vaccine Approaches , 2010, Cancer journal.

[71]  J. M. van der Hulst,et al.  Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses , 2010, Proceedings of the National Academy of Sciences.

[72]  C. Dutertre,et al.  The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8α+ dendritic cells , 2010, The Journal of experimental medicine.

[73]  Anna M. Keller,et al.  Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cells , 2010, The Journal of experimental medicine.

[74]  P. Rod Dunbar,et al.  Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens , 2010, The Journal of experimental medicine.

[75]  P. Kloetzel,et al.  Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells , 2010, The Journal of experimental medicine.

[76]  R. Ahmed,et al.  The role of mTOR in memory CD8+ T‐cell differentiation , 2010, Immunological reviews.

[77]  L. Zitvogel,et al.  Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway , 2010, Clinical Cancer Research.

[78]  Tomoki Ito,et al.  Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70. , 2010, Blood.

[79]  V. Pascual,et al.  A genomic approach to human autoimmune diseases. , 2010, Annual review of immunology.

[80]  S. Akira,et al.  Pattern Recognition Receptors and Inflammation , 2010, Cell.

[81]  R. Blasberg,et al.  Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts , 2010, The Journal of experimental medicine.

[82]  H. Ueno,et al.  Harnessing human dendritic cell subsets for medicine , 2010, Immunological reviews.

[83]  W. Heath,et al.  The CD8+ dendritic cell subset , 2010, Immunological reviews.

[84]  D. Gabrilovich,et al.  Regulation of dendritic cell differentiation and function by Notch and Wnt pathways , 2010, Immunological reviews.

[85]  P. Kantoff,et al.  Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  M. Nussenzweig,et al.  Origin and development of dendritic cells , 2010, Immunological reviews.

[87]  Steffen Jung,et al.  Defining dendritic cells by conditional and constitutive cell ablation , 2010, Immunological reviews.

[88]  Brigitta Stockinger,et al.  The functional plasticity of T cell subsets , 2009, Nature Reviews Immunology.

[89]  J. Berzofsky,et al.  Synergistic Enhancement of CD8+ T Cell–Mediated Tumor Vaccine Efficacy by an Anti–Transforming Growth Factor-β Monoclonal Antibody , 2009, Clinical Cancer Research.

[90]  C. Caux,et al.  Differences in tumor regulatory T-cell localization and activation status impact patient outcome. , 2009, Cancer research.

[91]  P. Schellhammer,et al.  Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer , 2009, Cancer.

[92]  L. Coussens,et al.  CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. , 2009, Cancer cell.

[93]  S. Quezada,et al.  Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies , 2009, The Journal of experimental medicine.

[94]  B. Pulendran,et al.  Modulation of adaptive immunity with Toll-like receptors. , 2009, Seminars in immunology.

[95]  Hideki Ueno,et al.  Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. , 2009, Immunity.

[96]  L. Lanier,et al.  Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction , 2009, The Journal of experimental medicine.

[97]  N. Romani,et al.  Targeting of epidermal Langerhans cells with antigenic proteins: attempts to harness their properties for immunotherapy , 2009, Cancer Immunology, Immunotherapy.

[98]  J. Winter,et al.  Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  P. Hwu,et al.  A phase III multi-institutional randomized study of immunization with the gp100: 209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  M. Tretiakova,et al.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. , 2009, Cancer research.

[101]  Anna M. Keller,et al.  Identification of a dendritic cell receptor that couples sensing of necrosis to immunity , 2009, Nature.

[102]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[103]  C. Figdor,et al.  DCIR is endocytosed into human dendritic cells and inhibits TLR8‐mediated cytokine production , 2009, Journal of leukocyte biology.

[104]  Bastian R. Angermann,et al.  Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses , 2008, The Journal of experimental medicine.

[105]  H. Okada,et al.  IL‐4 inhibits VLA‐4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit , 2008, European journal of immunology.

[106]  L. Zitvogel,et al.  Immunogenic cancer cell death: a key-lock paradigm. , 2008, Current opinion in immunology.

[107]  H. Ueno,et al.  Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. , 2008, Immunity.

[108]  H. Hammad,et al.  Cutting Edge: Alum Adjuvant Stimulates Inflammatory Dendritic Cells through Activation of the NALP3 Inflammasome , 2008, The Journal of Immunology.

[109]  D. Pennington,et al.  Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. , 2008, The Journal of clinical investigation.

[110]  V. Appay,et al.  CD8+ T cell efficacy in vaccination and disease , 2008, Nature Medicine.

[111]  J. Schlom,et al.  Paradigm Shifts in Cancer Vaccine Therapy , 2008, Experimental biology and medicine.

[112]  J. Connolly,et al.  Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I , 2008, Nature Immunology.

[113]  J. Connolly,et al.  Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. , 2007, Immunity.

[114]  H. Ueno,et al.  Dendritic cell subsets in health and disease , 2007, Immunological reviews.

[115]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[116]  T. Gajewski.  Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment , 2007, Clinical Cancer Research.

[117]  D. Petrylak,et al.  Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy , 2007, Clinical Cancer Research.

[118]  F. Villarroya,et al.  9-cis-Retinoic Acid (9cRA), a Retinoid X Receptor (RXR) Ligand, Exerts Immunosuppressive Effects on Dendritic Cells by RXR-Dependent Activation: Inhibition of Peroxisome Proliferator-Activated Receptor γ Blocks Some of the 9cRA Activities, and Precludes Them to Mature Phenotype Development1 , 2007, The Journal of Immunology.

[119]  C. Aspord,et al.  Breast cancer instructs dendritic cells to prime interleukin 13–secreting CD4+ T cells that facilitate tumor development , 2007, The Journal of experimental medicine.

[120]  R. Steinman,et al.  A subset of dendritic cells induces CD4+ T cells to produce IFN-γ by an IL-12–independent but CD70-dependent mechanism in vivo , 2007, The Journal of experimental medicine.

[121]  C. June,et al.  Principles of adoptive T cell cancer therapy. , 2007, The Journal of clinical investigation.

[122]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[123]  V. Lazar,et al.  αEβ7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis , 2007, The Journal of experimental medicine.

[124]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[125]  G. Parmiani,et al.  Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1 , 2007, The Journal of Immunology.

[126]  R. Steinman,et al.  Differential Antigen Processing by Dendritic Cell Subsets in Vivo , 2007, Science.

[127]  H. Ueno,et al.  Dendritic Cells Loaded With Killed Allogeneic Melanoma Cells can Induce Objective Clinical Responses and MART-1 Specific CD8+ T-cell Immunity , 2006, Journal of immunotherapy.

[128]  S. Jagannath,et al.  Enhancement of clonogenicity of human multiple myeloma by dendritic cells , 2006, The Journal of experimental medicine.

[129]  T. Waldmann.  The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design , 2006, Nature Reviews Immunology.

[130]  N. Bercovici,et al.  Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate , 2006, Cancer Immunology, Immunotherapy.

[131]  Ronald N. Germain,et al.  Extrafollicular Activation of Lymph Node B Cells by Antigen-Bearing Dendritic Cells , 2006, Science.

[132]  C. Sousa,et al.  Dendritic cells in a mature age , 2006, Nature Reviews Immunology.

[133]  S. Quezada,et al.  Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. , 2006, Current opinion in immunology.

[134]  Thierry Boon,et al.  Human T cell responses against melanoma. , 2006, Annual review of immunology.

[135]  Richard A Flavell,et al.  Transforming growth factor-beta regulation of immune responses. , 2006, Annual review of immunology.

[136]  C. Figdor,et al.  Internalizing Antibodies to the C-Type Lectins, L-SIGN and DC-SIGN, Inhibit Viral Glycoprotein Binding and Deliver Antigen to Human Dendritic Cells for the Induction of T Cell Responses , 2006, The Journal of Immunology.

[137]  B. Levine,et al.  CD28-mediated regulation of multiple myeloma cell proliferation and survival. , 2005, Blood.

[138]  R. Clynes,et al.  Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. , 2005, Immunity.

[139]  S. Akira,et al.  Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus , 2005, The Journal of experimental medicine.

[140]  Yu Wang,et al.  Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus , 2005, Nature.

[141]  S. Saeland,et al.  Cutaneous dendritic cells. , 2005, Seminars in immunology.

[142]  R. Steinman,et al.  Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients , 2005, The Journal of experimental medicine.

[143]  G. Coukos,et al.  The role of dendritic cell precursors in tumour vasculogenesis , 2005, British Journal of Cancer.

[144]  Guttorm Haraldsen,et al.  Primary antitumor immune response mediated by CD4+ T cells. , 2005, Immunity.

[145]  S. Rosenberg,et al.  CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.

[146]  M. Roncarolo,et al.  Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. , 2005, Blood.

[147]  D. Gabrilovich.  Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.

[148]  J. Blay,et al.  Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer , 2004, Clinical Cancer Research.

[149]  R. Darnell,et al.  Neuroimmunology of the paraneoplastic neurological degenerations. , 2004, Current opinion in immunology.

[150]  P. Carmeliet,et al.  Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer , 2004, Cancer Research.

[151]  R. Steinman,et al.  The Linkage of Innate to Adaptive Immunity via Maturing Dendritic Cells In Vivo Requires CD40 Ligation in Addition to Antigen Presentation and CD80/86 Costimulation , 2004, The Journal of experimental medicine.

[152]  J. Fay,et al.  Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells , 2004, The Journal of experimental medicine.

[153]  R. Steinman,et al.  In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.

[154]  A. Palucka,et al.  TNF Skews Monocyte Differentiation from Macrophages to Dendritic Cells 1 , 2003, The Journal of Immunology.

[155]  M. Jenkins,et al.  Antigen presentation to naive CD4 T cells in the lymph node , 2003, Nature Immunology.

[156]  O. Finn,et al.  Cancer vaccines: between the idea and the reality , 2003, Nature Reviews Immunology.

[157]  Virginia Pascual,et al.  Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. , 2003, Immunity.

[158]  Philippe Bousso,et al.  Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes , 2003, Nature Immunology.

[159]  M. Bevan,et al.  Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help , 2003, Science.

[160]  M. Jefford,et al.  Rational approaches to human cancer immunotherapy , 2003, Journal of leukocyte biology.

[161]  Michel C. Nussenzweig,et al.  Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance , 2002, The Journal of experimental medicine.

[162]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[163]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[164]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[165]  J. Banchereau,et al.  How dendritic cells and microbes interact to elicit or subvert protective immune responses. , 2002, Current opinion in immunology.

[166]  G. Schuler,et al.  Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells , 2002, The Journal of experimental medicine.

[167]  E. Gilboa,et al.  Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells , 2002, Annals of surgery.

[168]  D. Czerwinski,et al.  Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. , 2002, Blood.

[169]  David Allman,et al.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB , 2002, Nature Biotechnology.

[170]  T. Braun,et al.  Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. , 2001, Cancer research.

[171]  J. Banchereau,et al.  Interleukin 15 Skews Monocyte Differentiation into Dendritic Cells with Features of Langerhans Cells , 2001, The Journal of experimental medicine.

[172]  Michel C. Nussenzweig,et al.  Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo , 2001, The Journal of experimental medicine.

[173]  R. Steinman,et al.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.

[174]  M. Roncarolo,et al.  Type 1 T regulatory cells , 2001, Immunological reviews.

[175]  J. Banchereau,et al.  Sensing Pathogens and Tuning Immune Responses , 2001, Science.

[176]  Mark M. Davis,et al.  Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[177]  K. Black,et al.  Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. , 2001, Cancer research.

[178]  Nina Bhardwaj,et al.  Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells , 2001, The Journal of experimental medicine.

[179]  J. Banchereau,et al.  IL-6 switches the differentiation of monocytes from dendritic cells to macrophages , 2000, Nature Immunology.

[180]  Jay A. Berzofsky,et al.  NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway , 2000, Nature Immunology.

[181]  S. Miltenyi,et al.  BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood , 2000, The Journal of Immunology.

[182]  Simon C Watkins,et al.  The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells1 , 2000, The Journal of Immunology.

[183]  A. Mackensen,et al.  Phase I study in melanoma patients of a vaccine with peptide‐pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells , 2000, International journal of cancer.

[184]  J. Darnell,et al.  Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. , 2000, Cancer research.

[185]  L. Adorini,et al.  1α,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation , 2000, The Journal of Immunology.

[186]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[187]  E. Gilboa.  The makings of a tumor rejection antigen. , 1999, Immunity.

[188]  N. Kadowaki,et al.  The nature of the principal type 1 interferon-producing cells in human blood. , 1999, Science.

[189]  E. Engleman,et al.  Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study. , 1999, Blood.

[190]  H. Klocker,et al.  Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. , 1999, The Journal of urology.

[191]  A. Enk,et al.  Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. , 1999, Blood.

[192]  B. Pulendran,et al.  Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[193]  R. Maldonado-López,et al.  CD8α+ and CD8α− Subclasses of Dendritic Cells Direct the Development of Distinct T Helper Cells In Vivo , 1999, The Journal of experimental medicine.

[194]  Loise M. Francisco,et al.  Tumor-specific killer cells in paraneoplastic cerebellar degeneration , 1998, Nature Medicine.

[195]  Loise M. Francisco,et al.  Immature Dendritic Cells Phagocytose Apoptotic Cells via αvβ5 and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes , 1998, The Journal of experimental medicine.

[196]  D. Pardoll,et al.  The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.

[197]  A. N. Park,et al.  Interferon‐α and granulocyte‐macrophage colony‐stimulating factor differentiate peripheral blood monocytes into potent antigen‐presenting cells , 1998, Journal of leukocyte biology.

[198]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[199]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[200]  A. Enk,et al.  Induction of tolerance by IL-10-treated dendritic cells. , 1997, Journal of immunology.

[201]  J. Banchereau,et al.  CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. , 1997, Blood.

[202]  A. Aruffo,et al.  4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses , 1997, The Journal of experimental medicine.

[203]  G. Murphy,et al.  Phase I clinical trial: T‐cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA‐A0201‐specific peptides from prostate‐specific membrane antigen , 1996, The Prostate.

[204]  C. Haslett,et al.  Recognition of apoptotic cells by phagocytes , 1996, Experientia.

[205]  H. Weiner,et al.  Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. , 1996, The Journal of clinical investigation.

[206]  R. Darnell.  Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[207]  J. Banchereau,et al.  Activation of human dendritic cells through CD40 cross-linking , 1994, The Journal of experimental medicine.

[208]  H. Heslop,et al.  Donor T cells to treat EBV-associated lymphoma. , 1994, The New England journal of medicine.

[209]  R. Steinman,et al.  Proliferating dendritic cell progenitors in human blood , 1994, The Journal of experimental medicine.

[210]  C. Thompson,et al.  Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. , 1993, Journal of immunology.

[211]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[212]  T. Mosmann,et al.  IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. , 1991, Journal of immunology.

[213]  J. Posner,et al.  Paraneoplastic cerebellar degeneration: Clinical‐immunological correlations , 1988, Annals of neurology.

[214]  M. Moore,et al.  Mononuclear Phagocytes in Immunity Infection and Pathology , 1977, British Journal of Cancer.

[215]  R. Steinman,et al.  IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE , 1974, The Journal of experimental medicine.

[216]  Joseph White.  Between the Idea and the Reality , 1957, The Review of Politics.

[217]  A. Croockewit,et al.  Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. , 2013, Cancer research.

[218]  C. Melief,et al.  Cancer immunology. , 2011, Current opinion in immunology.

[219]  F. Batista,et al.  The who, how and where of antigen presentation to B cells , 2009, Nature Reviews Immunology.

[220]  J. Winter,et al.  Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[221]  Eva K. Lee,et al.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.

[222]  A. Palucka,et al.  Interactions of tumor cells with dendritic cells: balancing immunity and tolerance , 2008, Cell Death and Differentiation.

[223]  Shalin H. Naik,et al.  Steady-state and inflammatory dendritic-cell development , 2007, Nature Reviews Immunology.

[224]  M. S. Gordon.  Murine B16 Melanomas Expressing High Levels of the Chemokine Stromal-Derived Factor-1/CXCL12 Induce Tumor-Specific T Cell Chemorepulsion and Escape from Immune Control , 2007 .

[225]  Ira Mellman,et al.  Cell biology of antigen processing in vitro and in vivo. , 2005, Annual review of immunology.

[226]  V. Pascual,et al.  Dendritic cells control B cell growth and differentiation. , 2005, Current directions in autoimmunity.

[227]  T. Watts,et al.  TNF/TNFR family members in costimulation of T cell responses. , 2005, Annual review of immunology.

[228]  Yong‐jun Liu,et al.  IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. , 2005, Annual review of immunology.

[229]  Gerald Teschl,et al.  Functional Analysis , 2023, Texts and Readings in Mathematics.

[230]  W. Heath,et al.  Cross-presentation, dendritic cells, tolerance and immunity. , 2001, Annual review of immunology.

[231]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.

[232]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[233]  深浦彦彰.  Induction of Circulating Myelin Basic Protein and Proteolipid Protein-specific Transforming-Growth Factor-β1-secreting Th3 T Cells by Oral Administration of Myelin in Multiple Sclerosis Patients(ミエリン蛋白を経口投与された多発性硬化症患者におけるミエリン塩基性蛋白およびプロテオリピッドプロテイン特異的TGF-β1分泌性Th3T細胞の促進) , 1997 .

[234]  R. Furth.  Mononuclear phagocytes: In immunity, infection, and pathology , 1975 .

[235]  G. Parmiani,et al.  Immunobiology and Use in Clinical Trials Unique Human Tumor Antigens: , 2022 .

[236]  V. Vincek,et al.  A Feasibility Study , 2022 .